PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27378523-0	2016	Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.	dinaciclib	23-33	cyclin dependent kinase 9	Homo sapiens	90-94	
28361959-3	2017	In this report, we show that the CDKs inhibitor, Dinaciclib, selectively eliminates iPS cells without affecting the viability of cardiac cells.	dinaciclib	49-59	cyclin dependent kinase 9	Homo sapiens	33-37	
28361959-7	2017	Dinaciclib also inhibited the phosphorylation of Serine 2 of the C-terminal domain of RNA Polyemrase II through CDK9 inhibition.	dinaciclib	0-10	cyclin dependent kinase 9	Homo sapiens	112-116	
27486754-0	2016	Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.	dinaciclib	43-53	cyclin dependent kinase 9	Homo sapiens	14-39	
27486754-7	2016	These data support the importance of CDK9, in addition to CDK1, in mediating the growth inhibitory effect of dinaciclib in TNBC.	dinaciclib	109-119	cyclin dependent kinase 9	Homo sapiens	37-41	
27378523-4	2016	Here we show that a novel multiple-CDK inhibitor, dinaciclib (SCH727965, MK-7965), exhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK2 and CDK9.	dinaciclib	50-60	cyclin dependent kinase 9	Homo sapiens	191-195	
27378523-4	2016	Here we show that a novel multiple-CDK inhibitor, dinaciclib (SCH727965, MK-7965), exhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK2 and CDK9.	dinaciclib	62-71	cyclin dependent kinase 9	Homo sapiens	191-195	
27378523-4	2016	Here we show that a novel multiple-CDK inhibitor, dinaciclib (SCH727965, MK-7965), exhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK2 and CDK9.	dinaciclib	73-80	cyclin dependent kinase 9	Homo sapiens	191-195	
25578475-0	2015	CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.	dinaciclib	19-29	cyclin dependent kinase 9	Homo sapiens	0-4	
26766294-5	2016	Clinical studies of the drugs flavopiridol, dinaciclib, seliciclib, SNS-032 and RGB-286638 used as CDK9 inhibitors are also reviewed, with their additional targets and their relative IC50 values.	dinaciclib	44-54	cyclin dependent kinase 9	Homo sapiens	99-103	
25882699-3	2015	Here we explore drugs that cause loss of MCL1, particularly the potent new cyclin-dependent kinase inhibitor dinaciclib, which knocks down MCL1 by inhibiting CDK9.	dinaciclib	109-119	cyclin dependent kinase 9	Homo sapiens	158-162	
25962959-2	2015	Dinaciclib, a novel small molecule inhibitor of CDK1, CDK2, CDK5 and CDK9, is assessed in clinical trials for the treatment of several types of cancers.	dinaciclib	0-10	cyclin dependent kinase 9	Homo sapiens	69-73	
33686114-6	2021	We found that dinaciclib-triggered apoptosis is triggered by CDK9 inhibition and the resultant reduction in RNA pol II phosphorylation, which leads to the downregulation of the oncogenic marker MYC, and the anti-apoptotic protein MCL-1.	dinaciclib	14-24	cyclin dependent kinase 9	Homo sapiens	61-65	
25395429-2	2015	Dinaciclib is a novel potent small molecule inhibitor of cyclin-dependent kinases (CDK)1, CDK2, CDK5, and CDK9.	dinaciclib	0-10	cyclin dependent kinase 9	Homo sapiens	106-110	
25217392-1	2014	PURPOSE: Dinaciclib is a novel selective inhibitor of cyclin-dependent kinase (CDK)1, CDK2, CDK5, and CDK9.	dinaciclib	9-19	cyclin dependent kinase 9	Homo sapiens	102-106	
23053255-1	2012	PURPOSE: Dinaciclib, a selective inhibitor of cyclin-dependent kinase (CDK) 1, CDK2, CDK5, and CDK9, is metabolized via CYP3A4.	dinaciclib	9-19	cyclin dependent kinase 9	Homo sapiens	95-99	
34972202-2	2022	The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).	dinaciclib	147-157	cyclin dependent kinase 9	Homo sapiens	132-136	
32558295-3	2020	Exploring these mechanisms of resistance, we found that EML4-ALK cells parental or resistant to crizotinib, ceritinib or alectinib are remarkably sensitive to inhibition of CDK7/12 with THZ1 and CDK9 with alvocidib or dinaciclib.	dinaciclib	218-228	cyclin dependent kinase 9	Homo sapiens	195-199	
32375399-8	2020	Dinaciclib was shown to drastically enhance EV-T killing effects on cancer lines that express good levels of death receptor (DR) 5, which are associated with suppression of CDK1, CDK9 and anti-apoptotic proteins.	dinaciclib	0-10	cyclin dependent kinase 9	Homo sapiens	179-183